# A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Source: https://onco.cc/trials/nct06966700/  
OnCo record `nct06966700` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) is a phase 3 interventional study registered as NCT06966700 by Merck Sharp & Dohme LLC, with 2400 participants planned, started 2025-06-30 and due to reach its primary completion in 2033-03-23. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel and Doxorubicin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06966700
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 2400

## Sources

- ClinicalTrials.gov NCT06966700: https://clinicaltrials.gov/study/NCT06966700

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06966700.json